WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announces that it will invest $4.5 billion in its new manufacturing facility in Virginia, a proposed increase of $500m to support the enhanced manufacturing capability of a broader range of medicines including cancer treatments. This is part of the historic $50 billion investment announced in July 2025. The new facility will be located at Rivanna Futures in Albemarle County and is expected to create approximately 3,600 direct and indirect job. ...

In the current session, the stock is trading at $86.19, after a 0.94% increase. Over the past month, AstraZeneca Inc. (NASDAQ:AZN) stock increased by 6.27%, and in the past year, by 11.42%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.AstraZeneca P/E Compared to CompetitorsThe P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to ana ...

, /PRNewswire/ -- Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to test the ability of Turbine's platform to rationalize antibody-drug conjugate (ADC) discovery by predicting response mechanisms, informing ADC positioning, and reducing the need for large-scale cell line screens. This collaboration will apply Turbine's platform, which virtualizes biological experiments at scale, to not only improv ...

Key Takeaways AstraZeneca reported positive phase III Bax24 data in patients with resistant hypertension.Baxdrostat achieved a significant drop in 24-hour average systolic blood pressure versus placebo.Baxdrostat was well tolerated, and AstraZeneca plans to share results with global regulators.AstraZeneca (AZN) announced positive top-line data from the phase III Bax24 study evaluating the safety, tolerability and efficacy of its investigational candidate, baxdrostat, in patients with resistant hypertension. ...

每经编辑｜张喜威 胡玲 T V 诺贝尔化学奖公布 2 美国8月消费信贷变动数据公布 3 美联储理事巴尔发表讲话 1 四中全会前，人民日报连发八篇钟才文，传递什么信号 党的二十届四中全会将于10月20日至23日在北京召开。9月30日起，《人民日报》连续推出8篇"习近平经济思想指引下的中国经济专论"系列"钟才文"文章， 围绕"经济形势怎么看、经济工作怎么干"，深入系统阐述中国经济长期稳定发展的内在逻辑，以及中国发展之于世界的机遇性和确定性，传递出稳预期、强 信心、促发展的强烈信号。（人民日报经济社会） 2 隔夜市场 当地时间周二，美股三大指数集体收跌，道指跌0.2%，纳指跌0.67%，标普500指数跌0.38%，热门科技股多数下跌，特斯拉跌超4%，谷歌跌超1%，AMD 涨超3%。加密货币概念、半导体设备与材料跌幅居前，Strategy跌超8%，科休半导体跌超7%，科磊跌超4%，阿斯麦跌近4%。纳斯达克中国金龙指数收跌 2.24%，热门中概股普跌，世纪互联跌超6%，万国数据跌超5%，百度跌超4%，阿里巴巴、金山云跌超3%，哔哩哔哩跌近3%，京东、名创优品、理想汽车 跌超2%。 现货黄金涨0.59%，报3984.14 ...

Dow Index Breaks Winning Streak As AMD Soars On OpenAI Deal 10/06/2025The Dow Jones Industrial Average falls in Monday's stock market while the S&P 500 and the Nasdaq score record closes. 10/06/2025The Dow Jones Industrial Average falls in Monday's stock market... The IPO sector, despite concerns that the federal government shutdown might negatively impact the debut of new companies, remains fertile ground for intrepid growth investors. Natural gas producer BKV (BKV) and cybersecurity expert SailPoint (SAIL ...

Key Takeaways Thermo Fisher partners with AstraZeneca at BioVentureHub to drive collaborative R&D in life sciences.Thermo Fisher's new Gothenburg lab at BioVentureHub will support global pharma and biotech R&D by 2026.The AZN partnership advances drug and analytical development, reinforcing Thermo Fisher's mission globally.Thermo Fisher Scientific’s (TMO) clinical research business, PPD, announced a new research and development (R&D) partnership with AstraZeneca’s (AZN) BioVentureHub in Gothenburg, Sweden. ...

阿斯利康预计该药物的年销售额最高将超过50亿美元。 10月7日，阿斯利康表示，在研高血压药物baxdrostat在一项针对难治性高血压患者的后期临床试验中达 到主要目标，显著降低血压。阿斯利康计划将在年底前递交baxdrostat的审批，并预计该药物的年销售 额最高将超过50亿美元。该药物正在临床研究中的其他适应证还包括慢性肾病和预防心力衰竭。 ...

Authored by Evgenia Filimianova via The Epoch Times,The U.S. tariff policy and its unmatched pharmaceutical market are pulling European drugmakers to invest more heavily, from new manufacturing plants to U.S. stock listings and discount pricing deals.Since early 2025, European drugmakers have stepped up their U.S. presence. In the most recent move, the United Kingdom’s giant AstraZeneca announced on Sept. 29 a direct listing on the New York Stock Exchange, just months after pledging $50 billion of U.S. inve ...

Core Viewpoint - AstraZeneca's drug Baxdrostat successfully met the primary endpoint in a late-stage study for patients with treatment-resistant hypertension [1] Group 1 - The study focused on patients suffering from high blood pressure that is resistant to standard treatments [1] - The successful outcome of the study may enhance AstraZeneca's position in the hypertension treatment market [1]